EyeTherapy Blog News
Athena Vision launches; developing gene therapies for devastating eye diseases
Tue, 24 Nov 2015 11:53:39 +0000
Athena Vision is focused on developing gene therapies for eye diseases based on research conducted at UCL Today sees the launch of Athena Vision Limited a biopharmaceutical company focused on the development of gene therapies to treat a range of devastating eye diseases causing blindness. Launched by UCL Business PLC, the wholly-owned technology transfer company of UCL, […]Read more...
Registration for Retina Day 2015 Now Open!
Wed, 10 Jun 2015 11:37:25 +0000
It’s that time once agin for our annual research day for patients and the public. Retina Day 2015 is a free, one day event is organised by the Gene and Cell Therapy Group, UCL Institute of Ophthalmology and NIHR Moorfields Biomedical Research Centre. Come along to: * Hear about some of the latest innovations in research […]Read more...
UCL RPE65 Gene Therapy Trial Shows Benefit in People with Leber Congenital Amaurosis Type 2 for up to Three Years After Treatment
Tue, 05 May 2015 14:44:39 +0000
We are delighted to be able to announce that yesterday, Monday 4th May, the long-term results of our RPE65 gene therapy trial for Leber Congenital Amaurosis Type 2 (LCA2) were published in the prestigious New England Journal of Medicine. Begun in 2007, this was the world’s first-in-human trial of gene therapy to treat an inherited […]Read more...
Our research in the media
|Latest media coverage - July 2013|
Landmark media coverage
This BBC News24 item reports on the progress made in our clinical gene
therapy of gene therapy for LCA caused by damage to the RPE65 gene, the
first of it kind in the world.
This Channel 4 news item describes a breakthrough in the transplantation of retinal cells into the eye, where we showed for the first time that cells taken from the correct stage of eye development can integrate into the recipient retina and restore visual function in a model of blindness
Page last modified on 22 jul 13 14:26